Dopaminergic treatment in idiopathic restless legs syndrome: Effects on subjective sleepiness

Clinical Neuropharmacology

Volumn 33, Issue 6, 2010, Pages 276-278

  Kallweit, Ulf ^a   Khatami, Ramin ^a   Pizza, Fabio ^a,b   Mathis, Johannes ^c   Bassetti, Claudio L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Epworth sleepiness scale; excessive daytime sleepiness; L dopa; pramipexole; restless legs syndrome

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; PRAMIPEXOLE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DRUG EFFICACY; DRUG SAFETY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME; WAKEFULNESS;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; BENSERAZIDE; BENZOTHIAZOLES; CROSS-OVER STUDIES; DEPRESSION; DISORDERS OF EXCESSIVE SOMNOLENCE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; SLEEP STAGES; TIME FACTORS; WAKEFULNESS;

EID: 78650270941     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181fd82a1     Document Type: Article

References (12)

1. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
2. Popp R, Geisler P, Hirn C, et al. Increased daytime sleepiness in untreated RLS patients. J Sleep Res 2006;15:90.
3. Bassetti CL, Mauerhofer D, Gugger D, et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001;45:67-74.
4. Winkelman JW, Finn L, Young T. Prevalence and correlated of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006;7:545-552.
5. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
6. Clavadetscher SC, Gugger M, Bassetti CL. Restless legs syndrome: clinical experience with long-term treatment. Sleep Med 2004;5:495-500.
7. Möller JC, Körner Y, Cassel W, et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 2006;7:333-339.
8. Kallweit U, Siccoli MM, Poryazova R, et al. Excessive daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment. Eur Neurol 2009; 62:176-179.
9. Descombes S, Bonnet AM, Gasser UE, et al. Dual-release formulation, a novel principle in the levodopa treatment of Parkinson's disease. Neurology 2001;56:1239-1242.
10. Sforza E, Mathis J, Bassetti C. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med 2005;6:407-413.
11. Montplaisir J, De Champlain J, Young SN, et al. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF. Neurology 1982;32:1299-1302.
12. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27:1181-1194.